MDST Medicsight

    RNS Number : 2571K
  Medicsight Plc
  16 December 2008
   

    
 Press Release   16 December 2008


    Medicsight Plc

    ("Medicsight" or "the Company")

    Result of AGM

    Medicsight Plc (AIM: MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which
assists in the early detection of disease, confirms that all the resolutions put to shareholders at the Company's Annual General Meeting
held today were duly passed.

    - Ends -
    For further information:
 Medicsight plc
 David Sumner      +44 (0)20 7605 7950
                   www.medicsight.com 
 Nomura Code
 Jonathan Senior   +44 (0) 20 7776 1219 
 Juliet Thompson   +44 (0) 20 7776 1204
    Media enquiries:
 Abchurch                               +44 (0) 20 7398 7700
 Heather Salmond 
 Stephanie Cuthbert                     +44 (0) 20 7398 7718
 Simone Alves                           +44 (0) 20 7398 7728
 stephanie.cuthbert@abchurch-group.com  www.abchurch-group.com

    Notes to editors 
    Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software
for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the
colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD
software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data.
Medicsight's ColonCAD* and LungCAD* software products are seamlessly integrated with the advanced 3D visualisation workstations of several
industry-leading imaging equipment partners.

    About Computer-Aided Detection
    With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing
challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations
generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due
to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious
regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can
be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of
successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to
help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

    About Medicsight's CAD software
    Medicsight's ColonCAD* and LungCAD* software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically
highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such
as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

    Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The
integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of
demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users
to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world*s foremost clinicians in product related
areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development.
Medicsight also collaborates with a number of leading academic institutions and clinical research programs worldwide to develop the
Company*s comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight*s products to be validated to
the highest possible standards.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RAGDGMMZVVDGRZM

Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024